The estimated Net Worth of Vicki L Sato is at least $19.3 Milhão dollars as of 3 September 2024. Vicki Sato owns over 3,080 units of Vir Biotechnology Inc stock worth over $909,658 and over the last 21 years he sold VIR stock worth over $17,148,918. In addition, he makes $1,267,800 as Independent Chairman of the Board at Vir Biotechnology Inc.
Vicki has made over 132 trades of the Vir Biotechnology Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 3,080 units of VIR stock worth $77,000 on 3 September 2024.
The largest trade he's ever made was exercising 46,709 units of Vir Biotechnology Inc stock on 26 November 2003 worth over $368,067. On average, Vicki trades about 4,807 units every 37 days since 2003. As of 3 September 2024 he still owns at least 116,176 units of Vir Biotechnology Inc stock.
You can see the complete history of Vicki Sato stock trades at the bottom of the page.
Dr. Vicki L. Sato Ph.D. serves as Independent Chairman of the Board of the Company. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc. (“Vertex”), a publicly-traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen. Dr. Sato is a member of the board of directors of the following public companies: Bristol Myers Squibb Company, BorgWarner, Inc., Denali Therapeutics, Inc., and Syros Pharmaceuticals, Inc. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.
As the Independent Chairman of the Board of Vir Biotechnology Inc, the total compensation of Vicki Sato at Vir Biotechnology Inc is $1,267,800. There are 3 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
Vicki Sato is 71, he's been the Independent Chairman of the Board of Vir Biotechnology Inc since 2016. There are 3 older and 19 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
Vicki's mailing address filed with the SEC is C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., eKristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: